National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cerliponase alfa (Brineura®) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

NCPE Assessment Process Complete
Rapid review commissioned 11/10/2017
Rapid review completed 27/11/2017
Rapid Review Outcome A full pharmacoeconomic evaluation is recommended.